Send us a text
Dr. Wade Blair, Ph.D. is Head of Virology and Vaccine Discovery, Vaccines and Immune Therapies, at AstraZeneca ( https://www.astrazeneca.com/ ). Dr. Blair did his Ph.D. in Microbiology at University of California, Irvine - College of Medicine, did Postdoctoral Research at Duke University in HIV, and has held positions of increasing responsibility across both therapeutic and vaccine domains, including positions at both major pharma companies like BMS, Pfizer, Merck, Gilead and Genentech, as well as some smaller biotech companies. Over his impressive career, Dr. Blair contributed to the discovery and/or development of several approved drugs and molecules in late-stage clinical trials, including the HIV protease inhibitor atazanavir; the HIV non-nucleoside reverse transcriptase inhibitor doravirine; the HIV attachment inhibitor fostemsavir; the HIV capsid inhibitor lenacapavir; and letermovir, a treatment for cytomegalovirus (CMV) infections.
Support the show
View all episodes
By Ira Pastor
5
22 ratings
Send us a text
Dr. Wade Blair, Ph.D. is Head of Virology and Vaccine Discovery, Vaccines and Immune Therapies, at AstraZeneca ( https://www.astrazeneca.com/ ). Dr. Blair did his Ph.D. in Microbiology at University of California, Irvine - College of Medicine, did Postdoctoral Research at Duke University in HIV, and has held positions of increasing responsibility across both therapeutic and vaccine domains, including positions at both major pharma companies like BMS, Pfizer, Merck, Gilead and Genentech, as well as some smaller biotech companies. Over his impressive career, Dr. Blair contributed to the discovery and/or development of several approved drugs and molecules in late-stage clinical trials, including the HIV protease inhibitor atazanavir; the HIV non-nucleoside reverse transcriptase inhibitor doravirine; the HIV attachment inhibitor fostemsavir; the HIV capsid inhibitor lenacapavir; and letermovir, a treatment for cytomegalovirus (CMV) infections.
Support the show
14,198 Listeners
39,948 Listeners
2,170 Listeners